Skip to content
DataLookout
Menu

NCT02452008

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 6, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints revised (3)
    • Primary endpoint revised
    • Publications: details revised at 1 of 1 entry
  2. Minor Primary completion date changed from estimate of Dec 2025 to Dec 8, 2025
    • Study completion date: May 2026 to Dec 2026
    v20
  3. Notable Primary completion date: May 2025 to Dec 2025
    • Collaborators: 1 to 2
    v19
  4. Notable Primary completion date: Oct 2024 to May 2025
    • Study completion date: Dec 2025 to May 2026
    v18
  5. Notable Eligibility criteria expanded, about 7 words
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 2024 to Oct 2024
    • Site details revised at 4 of 4 sites
    v17
Show 15 earlier versionsHide 15 earlier versions
  1. Notable Primary completion date: Jun 2023 to Jun 2024
    • Study completion date: Dec 2023 to Dec 2025
    v16
  2. Notable Primary completion date: Jun 2022 to Jun 2023
    • Study completion date: Dec 2022 to Dec 2023
    v15
  3. Minor Primary completion date: Dec 2021 to Jun 2022v14
  4. Minor Site details revised at 1 of 4 sitesv13
  5. Minor Primary completion date: Jul 2021 to Dec 2021
    • Study completion date: Jul 2021 to Dec 2022
    v12
  6. Notable Primary completion date: Jul 2020 to Jul 2021v11
  7. Notable Primary completion date: Jul 2019 to Jul 2020
    • Start date: Apr 2016 to May 3, 2016
    v10
  8. Minor Collaborators expanded, about 4 wordsv9
  9. Minor Site details revised at 1 of 4 sitesv8
  10. Minor Study sites: 3 to 4v7
  11. Minor Study sites: 2 to 3v6
  12. Minor Study completion date: Jul 2021v5
  13. Notable Eligibility criteria expanded, about 6 wordsv4
  14. Minor Study sites: 1 to 2
    • Study title expanded, about 1 word
    v3
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2015 to Apr 2016
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.
Timeframe: 8 years

Secondary (3)

Number of Participants With (PSA50) Response
Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).
Number of Patients Experiencing Treatment-related Toxicities

Arms and interventions

Arm 1: Enzalutamide with LY2157299Experimental
Arm 2: Enzalutamide aloneExperimental

Drugs: Enzalutamide, LY2157299

Sites

4 sites in 1 country